Diss. (sammanfattning) Linköping : Univ., 2004. / Härtill 5 uppsatser.

Alteração da fosfolipase A2 tem sido descrita em diversas doenças neuropsiquiátricas. Esta enzima é responsável pelo metabolismo dos fosfolípides de membrana e parece estar envolvida na fisiopatologia do transtorno bipolar. Neste estudo, foram analisados os três principais subtipos da PLA2 (sPLA2, cPLA2 e iPLA2) em plaquetas de pacientes e indivíduos controles. A atividade de subtipos de PLA2 foi determinada em 20 pacientes TB sem tratamento com estabilizadores de humor e após seis semanas de tratamento com lítio; 72 pacientes medicados e 65 controles (16 pareados com os pacientes sem tratamento e 49 com os pacientes previamente medicados), pelo método radioenzimático. Os pacientes foram diagnosticados e classificados de acordo com os critérios estabelecidos no DSM-IV-TR. Foi verificado que Os pacientes no estágio inicial da doença apresentaram menor atividade de iPLA2, sPLA2 e cPLA2 quando comparadas ao grupo controle. Seis semanas de tratamento com o lítio não foram suficientes para observar alterações nos resultados obtidos. No entanto, o lítio diminuiu a sintomatologia maníaca e a depressiva, avaliadas pelas escalas de Hamilton e Young, respectivamente (p < 0,01 para as duas comparações). Os pacientes medicados não diferiram do grupo controle para os três subtipos de PLA2 avaliados. Estes resultados sugerem que no estágio inicial do TB há uma diminuição da atividade das PLA2, e que a ação de um ou mais medicamentos que são incluídos na terapêutica para este transtorno podem reverter essa diminuição. Sugere-se ainda que a diminuição da atividade da iPLA2 no estágio inicial do transtorno bipolar, além de alterar o remodelamento da membrana, possa ser um fator de risco para o desenvolvimento de demência nestes pacientes. / Changes in phospholipase A2 have been reported in several psychiatric disorders. This enzyme is responsible for the metabolism of membrane phospholipids and has been suggested to play a role in bipolar disorder physiopathology. In this study, the activity of the three main subtypes of phospholipase A2 (PLA2) were analyzed (sPLA2, cPLA2 and iPLA2) in platelets of BD patients and health subjects. Subjects enrolled were: 20 drug-naïve and drug free BD patients, who were treated with lithium for six weeks; 72 BD long-term treatment patients and 65 controls (16 for the drug-naïve and drug free and 49 for the long term group). PLA2 subtype activities were determined by the radio enzymatic method. Patients\' diagnostic and classification were made according to DSM-IV-TR criteria. Patients at the early stage of the disease presented lower iPLA2, sPLA2 and cPLA2 activity than the control group. Six weeks treatment with lithium did not change these activities. However, lithium reduced the maniac and depressive symptoms, evaluated with Hamilton and Young scales, respectively (p < 0.01, for both comparisons). Long-term treated patients presented similar PLA2 activities to control group. The results suggest that at the early stage of BD iPLA2 activity is decreased and that the adequate treatment of BD could reverse this reduction. We suggest that a reduction of iPLA2 activity at the early stage of BD can modify the membrane metabolism, and could be a risk for the development of dementia in BD patients.

Reproduction de : Thèse de doctorat : Stratégies d'exploitation des fonctions biologiques : Lille 1 : 2005. / N° d'ordre (Lille 1) : 3672. Articles en anglais intégrés au texte. Résumé en français et en anglais. Titre provenant de la page de titre du document numérisé. Bibliogr. f. 129-146. Liste des communications et publications.

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that is characterized by widespread focal areas of inflammation and demyelination. Although the exact cause of the disease is still not known, myelin-reactive T cells that enter the CNS trigger the disease and lead to the recruitment and activation of macrophages and other immune cells. One set of candidates that could serve to mediate these CNS changes is the family of phospholipase A2 (PLA2) enzymes, which consist of secreted (sPLA2) and cytosolic (cPLA2) forms. These enzymes hydrolyze membrane phospholipids to release free fatty acids (arachidonic acid) that can stimulate complex inflammatory cascades, and lysophospholipids that can induce myelin breakdown and demyelination, the two pathological hallmarks of MS. / For my Ph.D. research I studied the expression and role of different members of the PLA2 family in 'experimental autoimmune encephalomyelitis' (EAE), a widely used animal model of MS. I first generated a relapsing-remitting form of EAE in the C57BL/6 mouse strain that lacks a major form of sPLA2. I showed that cPLA2 is expressed by immune cells in the EAE lesions in the CNS. Furthermore blocking the activity of cPLA2 with a broad-spectrum chemical inhibitor starting at the time of EAE induction reduced the incidence and severity of disease, reduced lesion burden as well as reduced the expression of a number of chemokines and cytokines. Treating mice in the remission phase also prevented further clinical episodes. This showed that some or all members of the cPLA2 family play an important role in the onset and progression of EAE in a strain of mice lacking sPLA2. / I next carried out studies to assess the expression of all 14 members of the sPLA2 and cPLA2 families at the onset, peak and remission stages of EAE in the SJL/J mouse strain that expresses all forms of PLA2. The mRNA expression of only 4 of these PLA2s was increased. These include sPLA2 (groups IIA and V) and cPLA 2 (groups IVA and VIA). The expression of these PLA2s in the CNS was also characterized by double-immunofluorescence. The role of these PLA2s was assessed using selective inhibitors and analysed by monitoring the clinical disability scores, chemokine/cytokine protein arrays, lipomics lipid profiling, and histological analysis. Surprisingly, the sPLA2 inhibitor prevented disease remission and worsened the clinical outcome. This was accompanied by an increase in several pro-inflammatory chemokines. Selective inhibitors of cPLA2 group IVA and the calcium independent foam group VIA (iPLA2) reduced severity of EAE when given starting before onset of disease. The cPLA2 inhibitor treatment was effective only while administered, while iPLA2 inhibitor treatment was effective even after treatment was stopped. Furthermore, only delayed treatment with the iPLA2 inhibitor was effective, suggesting that cPLA2 group IVA only plays a role in the initiation of disease, while iPLA 2 plays a role in both disease onset and progression. These effects were also associated with concomitant reduction in chemokine/cytokine expression, reduction of inflammatory lipid mediators, and increase in protective lipids e.g., omega 3 fatty acids. / This work has allowed us to dissect out the expression and role of different members of the PLA2 family and has revealed the importance of selectively inhibiting some but not others in EAE. These findings may therefore have important implications for the treatment of MS.

Diss. (sammanfattning) Uppsala : Uppsala universitet, 2008. / Härtill 4 uppsatser.

Thesis (Ph. D.)--University of Missouri--Columbia, 2002. / "May 2002." Typescript. Includes bibliographical references. Also available on the Internet.

Thesis (M.S.)--Biomedical Engineering, Georgia Institute of Technology, 2009. / Committee Chair: Boyan, Barbara; Committee Member: Eskin, Suzanne; Committee Member: Lobachev, Kirill; Committee Member: Schwartz, Zvi. Part of the SMARTech Electronic Thesis and Dissertation Collection.

Orientadores: Sergio Marangoni, Luis Alberto Ponce-Soto / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-10T18:20:05Z (GMT). No. of bitstreams: 1 Bonfim_VeraLucia_D.pdf: 7120787 bytes, checksum: 3839207f36a378b463b63406202ef7e4 (MD5) Previous issue date: 2008 / Resumo: O envenenamento ofídico é um evento comum nos países pobres da área tropical e subtropical e as conseqüências deste, muito graves. Nestes países, pequena têm sido a valorização destas conseqüências, sendo pouco registradas estatisticamente como casos de saúde pública e muitas vezes tratados com procedimentos pouco efetivos ou ultrapassados. Neste trabalho foram utilizados metodologias refinadas e protocolos otimizados de purificação em HPLC com o intuito de se estudar mais detalhadamente a composição do veneno de duas serpentes de importância médica e epidemiológica, Bothrops jararacussu e Calloselasma rhodostoma, e analisar a relação estrutura função de PLA2 D49 (6-1, 6-2 e Cr-IV1) e PLA2 homólogas K49 (Bj-VII e Cr 5). A Bothrops jararacussu, é uma serpente encontrada nas Américas, desde o México até a Argentina sendo que no Brasil cerca de 90% dos acidentes ofídicos são causados pelo gênero Bothrops. A Calloselasma rhodostoma, é uma serpente amplamente distribuída no sudeste da Ásia e é a causa mais comum de acidentes ofídicos na Malásia e Tailândia. As novas toxinas foram obtidas com alto grau de pureza e homogeneidade molecular, como mostram os perfis cromatográficos, eletroforéticos e de espectrometria de massa por MALDi-TOF. A nova PLA2 D49 foi purificada do veneno de Calloselasma rhodostoma após dois passos cromatográficos: exclusão molecular em uma coluna Protein Pack SW 300 (0,78 cm x 3,30 cm), eluída com 0,25M de bicarbonato de amônio, pH 7,9, a um fluxo de 0,3 ml/min e, fase reversa em HPLC usando uma coluna µ-Bondapack C-18. Esta apresentou atividade fosfolipásica de 14,25±0,36 nmol/mg/min na presença de substrato sintético cromogênico (4-nitro-3-(octanoyloxy) benzoic acid), massa molecular de 14,029 Da determinada através de espectrometria de massa por MALDI-TOF, valor calculado de pI igual a 8.55, caráter básico e grande homologia seqüencial evidenciada pela estrutura primária quando esta é comparada com outras PLA2 D49 provenientes de veneno de serpente. A outra proteína, denominada Cr 5, uma PLA2 homóloga K49 foi isolada do veneno de Calloselasma rhodostoma em um único passo cromatográfico de fase reversa em HPLC (µ-Bondapack C-18). A massa molecular de 13,965 Da foi determinada através de espectrometria de massa por MALDI-TOF. A composição de aminoácido mostrou que a Cr 5 tem alto conteúdo de Lys, Tyr, Gly, Pro e 14 cisteínas, resíduos típicos de uma PLA2 básica. A completa seqüência de aminoácidos da Cr 5 contém 120 resíduos e mostra alta identidade quando comparada a outras PLA2 K49 isoladas de venenos de serpentes da família viperidae. Com relação à caracterização biológica, esta foi realizada também com as isoformas 6-1 e 6-2 (provenientes da fração BthTX-II de Botrhops jararacussu) e com a PLA2 K49 Bj-VII, estas purificadas e parcialmente caracterizadas em trabalho anterior. As PLA2 6-1, 6-2 e Cr-IV 1, exibiram miotoxicidade local e na dosagem de 40 µg/150 µl a 6-1 causou 83,06% de citotoxicidade em miotubos e 93,78% em mioblastos, já a 6-2 75,12 % em miotubos e 86,26% em mioblastos e a Cr-IV 1, 91,50% e 88,40% de citotoxicidade em miotubos e mioblastos, respectivamente. O efeito citotóxico também foi visto em fibroblastos mostrando na dosagem de 5 µM (linhagem 3T3) 85,63%, 86% e 91,34% de citotoxicidade na presença de 6-1, 6-2 e Cr-IV 1 respectivamente, e na linhagem COS7, 95,42%, 95,07% e 96,42% respectivamente, além de atividade inflamatória, sendo esta mais pronunciada na presença da Cr-IV 1. As PLA2s K49 homólogas, Bj-VII e Cr 5, evidenciaram miotoxicidade local e na dosagem de 40 ug/150 µl, a Bj-VII causou 87±50% de lise em mioblastos e 84±85% em miotubos e 91±25% de lise em mioblastos e 91±0.8 % em miotubos quando em contato com a Cr 5, além de atividade inflamatória evidenciada pela indução de edema. No caso destas proteínas, todos os efeitos biológicos induzidos por elas ocorreram na ausência de atividade fosfolipásica mensurável in vitro, suportando a idéia proposta pela literatura de mecanismos catalíticos e farmacológicos independentes. Apesar de todas apresentarem algumas diferenças biológicas, elas possuem um comportamento semelhante na estrutura-função, sugerindo uma ancestralidade comum embora sejam proteínas provenientes de venenos de serpentes separadas geograficamente / Abstract: Snake poisoning is a common event in poor countries of tropical and subtropical areas and the consequences of this is very serious. In these countries, there is the valorization of these consequences, due to few registers of published health cases and a lot of times treated with procedures a little effective or outdated. In this work we refined methodologies and optimized purification protocols used in HPLC with the intention to study the composition of the venom of two serpents of epidemic importance, Bothrops jararacussu and Calloselasma rhodostoma, and to analyze the relationship of structures function of PLA2 D49 (6-1, 6-2 and Cr-IV1) and homologous PLA2 K49 (Bj-VII and Cr 5). Bothrops jararacussu is a serpent found in America, from Mexico to Argentina being in Brazil, about 90% of the snake accidents caused by Bothrops genus. Calloselasma rhodostoma is a serpent thoroughly distributed at the Southwest of Asia and it is the most common cause of snake accidents in Malaysia and Thailand. The new toxins were obtained with high degree of purity and molecular homogeneity, like showed the chromatographics profiles, electrophoresis and MALDi-tof mass spectrometric (MS) analysis. A new D49 PLA2 was purified from the venom of Calloselasma rhodostoma after two chromatographic steps; molecular exclusion was loaded onto a Protein-Pack 300 SW column (0.78 cm 3 30 cm) and eluted with 0.25 M ammonium bicarbonate, pH 7.9, at a flow rate of 0.3 ml/min and reverse phase HPLC on µ-Bondapack C-18 and showed phospholipasic activity of 14.25±0.36 nmol/mg/min in the presence of a synthetic chromogenic substrate (4-nitro-3-(octanoyloxy) benzoic acid), a molecular mass of 14.029 Da was determined by MALDI-TOF mass spectrometry, calculated pI value 8.55, basic character and great sequential homology evidenced by the primary structure when this was compared with other PLA2 from D49 snake venom. The other protein, denominated Cr 5 PLA2 homologous (K49) was isolated from Calloselasma rhodostoma venom in one chromatographic step in reverse phase HPLC (RP-HPLC) (on l-Bondapack C-18). A molecular mass of 13.965 Da was determined by MALDI-TOF mass spectrometry. The amino acid composition showed that Cr 5 had a high content of Lys, Tyr, Gly, Pro, and 14 half-Cys residues, typical residues of a basic PLA2. The complete amino acid sequence of Cr 5 PLA2 contains 120 residues and this sequence shows high identity values when compared to other K49 PLA2s isolated from the venoms of viperid snakes. In relation with biological characterization, this was also done with the isoforms 6-1 and 6-2 (from fraction BthTX-II of Botrhops jararacussu) and with PLA2 K49 Bj-VII, these purified and partially characterized in The Masters. PLA2 6-1, 6-2 and Cr-IV 1 exhibited in mice local myonecrosis and edema upon intramuscular and intravenous injections, respectively. In dosage of 40 ug/150 ml, 6-1 showed 83.06% of citotoxicity in myotubes and 93.78% in myoblasts, 6-2 showed 75,12 % in myotubes and 86,26% in myoblasts, to Cr-IV 1 91.50% and 88.40% of citotoxicity in myoblasts and myotubes respectively. The citotoxic effect also in fibroblasts (cell line 3T3 and COS7) and in dosage de 5 µM (cell line 3T3) 85.63%, 85% and 91.34% of citotoxicity in the presence of 6-1, 6-2 and Cr-IV 1 respectively, and lineage COS7, 95.42%, 95.07 and 96.42% respectively, besides inflammatory activity, being this one more pronounced in the presence of the Cr-IV 1. PLA2 homologue K49, Bj-VII and Cr 5, evidenced local myotoxicity and in dosage of 40 ug/150 ml, showed 87±50 of lise in myoblasts and 84±85 in myotubes and 91±25% and 91±0.8 % when in contact with Bj-VII and Cr 5, respectivally besides of inflammatory activity evidenced by the edema induction. In the case of PLA2 K49 (Bj-VII and Cr 5), all of the biological effects induced by them happened in the absence of activity phospholipase measurable in vitro, supporting the idea proposed by the literature of catalytic and pharmacological mechanisms independent. Even though all show some kind of biologic differences all of them have a similar behave in function and structure which suggests a common ascendance of course we know they are proteins coming from different snakes geographic separated. / Doutorado / Bioquimica / Doutor em Biologia Funcional e Molecular

Alteração da fosfolipase A2 tem sido descrita em diversas doenças neuropsiquiátricas. Esta enzima é responsável pelo metabolismo dos fosfolípides de membrana e parece estar envolvida na fisiopatologia do transtorno bipolar. Neste estudo, foram analisados os três principais subtipos da PLA2 (sPLA2, cPLA2 e iPLA2) em plaquetas de pacientes e indivíduos controles. A atividade de subtipos de PLA2 foi determinada em 20 pacientes TB sem tratamento com estabilizadores de humor e após seis semanas de tratamento com lítio; 72 pacientes medicados e 65 controles (16 pareados com os pacientes sem tratamento e 49 com os pacientes previamente medicados), pelo método radioenzimático. Os pacientes foram diagnosticados e classificados de acordo com os critérios estabelecidos no DSM-IV-TR. Foi verificado que Os pacientes no estágio inicial da doença apresentaram menor atividade de iPLA2, sPLA2 e cPLA2 quando comparadas ao grupo controle. Seis semanas de tratamento com o lítio não foram suficientes para observar alterações nos resultados obtidos. No entanto, o lítio diminuiu a sintomatologia maníaca e a depressiva, avaliadas pelas escalas de Hamilton e Young, respectivamente (p < 0,01 para as duas comparações). Os pacientes medicados não diferiram do grupo controle para os três subtipos de PLA2 avaliados. Estes resultados sugerem que no estágio inicial do TB há uma diminuição da atividade das PLA2, e que a ação de um ou mais medicamentos que são incluídos na terapêutica para este transtorno podem reverter essa diminuição. Sugere-se ainda que a diminuição da atividade da iPLA2 no estágio inicial do transtorno bipolar, além de alterar o remodelamento da membrana, possa ser um fator de risco para o desenvolvimento de demência nestes pacientes. / Changes in phospholipase A2 have been reported in several psychiatric disorders. This enzyme is responsible for the metabolism of membrane phospholipids and has been suggested to play a role in bipolar disorder physiopathology. In this study, the activity of the three main subtypes of phospholipase A2 (PLA2) were analyzed (sPLA2, cPLA2 and iPLA2) in platelets of BD patients and health subjects. Subjects enrolled were: 20 drug-naïve and drug free BD patients, who were treated with lithium for six weeks; 72 BD long-term treatment patients and 65 controls (16 for the drug-naïve and drug free and 49 for the long term group). PLA2 subtype activities were determined by the radio enzymatic method. Patients\' diagnostic and classification were made according to DSM-IV-TR criteria. Patients at the early stage of the disease presented lower iPLA2, sPLA2 and cPLA2 activity than the control group. Six weeks treatment with lithium did not change these activities. However, lithium reduced the maniac and depressive symptoms, evaluated with Hamilton and Young scales, respectively (p < 0.01, for both comparisons). Long-term treated patients presented similar PLA2 activities to control group. The results suggest that at the early stage of BD iPLA2 activity is decreased and that the adequate treatment of BD could reverse this reduction. We suggest that a reduction of iPLA2 activity at the early stage of BD can modify the membrane metabolism, and could be a risk for the development of dementia in BD patients.

The host eosinophil response was compared in mice infected with either T. spiralis or T. pseudospiralis by determination of levels of splenic and intestinal phospholipase B, a marker enzyme for eosinophils. Primary infection of naive mice and challenge infection of homologously sensitized mice with T. pseudospiralis resulted in significantly lower tissue phospholipase B activities than infection with T. spiralis. Mice homologously challenged with T. pseudospiralis did exhibit an anamnestic eosinophil response compared to mice given a primary T. pseudospiralis infection. This anamnestic response, however, was significantly lower than the eosinophil response seen in sensitized mice given a homologous T. spiralis challenge. Mice sensitized to T. spiralis or T. pseudospiralis and heterologous challenge demonstrated an elevated eosinophil response compared to mice given a primary infection with either parasite. The heterologous challenge response, however, was not as intense as found for sensitized mice given a homologous challenge.